Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06117917

Esketamine Combined With Pregabalin on CPSP in Spinal Patients.

Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients Undergoing Primary Spinal Tumor Surgery.

Sponsor: Beijing Tiantan Hospital

Conditions Chronic Post Operative Pain Esketamine Pregabaline

Interventions Normal saline and placebo capsule S-ketamine and pregabalin

Updated 4 times since 2023 Last updated: Oct 31, 2023 Started: Nov 10, 2023 Primary completion: May 31, 2024 Completion: Jun 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06117917, this PHASE2/PHASE3 trial focuses on Chronic Post Operative Pain and Esketamine and remains ongoing. Sponsored by Beijing Tiantan Hospital, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Nov 2025 — Present [monthly]

Unknown PHASE2/PHASE3

Status: Not Yet Recruiting → Unknown
Sep 2024 — Nov 2025 [monthly]

Not Yet Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China